NCT01811849View on ClinicalTrials.gov

Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Type 1 Diabetes
Interventions
DRUG

Insulin LISPRO

DRUG

Insulin LISPRO

DRUG

Insulin LISPRO

Sponsors

Lead Sponsor

Biodel
All Listed Sponsors
lead

Biodel

INDUSTRY